Trial Profile
Effect of the CRTH2 Antagonist OC459 on the Response to Rhinovirus Challenge in Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Timapiprant (Primary)
- Indications Acute asthma; Asthma
- Focus Therapeutic Use
- Acronyms ORCA
- 29 Oct 2021 Primary endpoint has not been met (Total Lower Respiratory Symptom Score) , according to Results published in the Thorax
- 29 Oct 2021 Results published in the Thorax
- 20 Feb 2019 Status changed from recruiting to completed.